Sysmex (OTCMKTS:SSMXY) Issues FY 2026 Earnings Guidance

Sysmex (OTCMKTS:SSMXY – Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.370-0.370 for the period, compared to the consensus EPS estimate of 0.440. The company issued revenue guidance of $3.4 billion-$3.4 billion, compared to the consensus revenue estimate of $3.1 billion.

Analyst Ratings Changes

Separately, Citigroup cut Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold”.

Get Sysmex alerts:

Check Out Our Latest Stock Analysis on Sysmex

Sysmex Stock Performance

OTCMKTS SSMXY opened at $8.12 on Friday. Sysmex has a 1-year low of $8.12 and a 1-year high of $18.10. The company has a market capitalization of $5.11 billion, a P/E ratio of 16.92 and a beta of 1.10. The business has a 50 day moving average price of $8.73 and a 200 day moving average price of $9.39. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44.

Sysmex (OTCMKTS:SSMXY – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). Sysmex had a net margin of 8.86% and a return on equity of 9.27%. The firm had revenue of $877.92 million during the quarter, compared to analysts’ expectations of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. Sell-side analysts expect that Sysmex will post 0.44 EPS for the current fiscal year.

About Sysmex

(Get Free Report)

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.

Recommended Stories

• Five stocks we like better than Sysmex
• Aeluma’s Post-Earnings Dip Creates a Buying Opportunity
• Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
• 2 Ways to Play the Big Pharma Patent Cliff
• YETI Rallies After Earnings Beat and Raised Outlook

Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.